The Latest News July 29, 2021 argenx Reports Half Year 2021 Financial Results and Provides Second Quarter Business Update Breda, the Netherlands argenx today announced its half year 2021 financial results and provided a second quarter business update and outlook for the remainder of the year. Read argenx Reports Half Year 2021 Financial Results and Provides Second Quarter Business Update More Press Releases News July 22, 2021 argenx to Report Half Year 2021 Financial Results and Second Quarter Business Update on July 29, 2021 argenx today announced that it will host a conference call and audio webcast on Thursday, July 29, 2021 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its half year 2021 financial results and provide a second quarter business update. Read News July 14, 2021 argenx to Host Virtual R&D Day on July 20, 2021 argenx today announced that it will host a virtual R&D Day on Tuesday, July 20, 2021 at 3:00 p.m. CET (9:00 a.m. ET) to highlight its ‘argenx 2025 Read News June 16, 2021 argenx announces publication of Phase 3 ADAPT trial results of efgartigimod for the treatment of generalized myasthenia gravis in The Lancet Neurology argenx today announced that The Lancet Neurology has published pivotal trial results from the Phase 3 ADAPT trial of efgartigimod, an FcRn antagonist, for the treatment of adults living with generalized myasthenia gravis (gMG). Read Media center ARGX-118 CIDP Cusatuzumab Efgartigimod Immune Thrombocytopenia Myasthenia Gravis Pemphigus Vulgaris SIMPLE Antibody Platform Facet Tags May 1, 2020 Making Asthma Crystal Clear April 16, 2020 Monoclonal antibodies against GARP/TGF-b1 complexes inhibit the immunosuppressive activity of human regulatory T cells in vivo April 13, 2020 ARGX-116 / A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels April 8, 2020 Protein crystallization promotes type 2 immunity and is reversible by antibody treatment April 7, 2020 SIMPLE Antibody platform / Dual anti-idiotypic purification of a novel, native-format biparatopic anti-MET antibody with improved in vitro and in vivo efficacy Load more
News July 22, 2021 argenx to Report Half Year 2021 Financial Results and Second Quarter Business Update on July 29, 2021 argenx today announced that it will host a conference call and audio webcast on Thursday, July 29, 2021 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its half year 2021 financial results and provide a second quarter business update. Read
News July 14, 2021 argenx to Host Virtual R&D Day on July 20, 2021 argenx today announced that it will host a virtual R&D Day on Tuesday, July 20, 2021 at 3:00 p.m. CET (9:00 a.m. ET) to highlight its ‘argenx 2025 Read
News June 16, 2021 argenx announces publication of Phase 3 ADAPT trial results of efgartigimod for the treatment of generalized myasthenia gravis in The Lancet Neurology argenx today announced that The Lancet Neurology has published pivotal trial results from the Phase 3 ADAPT trial of efgartigimod, an FcRn antagonist, for the treatment of adults living with generalized myasthenia gravis (gMG). Read
